Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools

Clinical Pharmacokinetics

Volumn 43, Issue 12, 2004, Pages 823-832

  Sankatsing, Sanjay U C ^a,b   Hoggard, Patrick G ^c   Huitema, Alwin D R ^d   Sparidans, Rolf W ^e   Kewn, Stephen ^c   Crommentuyn, Kristel M L ^d   Lange, Joep M A ^a,b   Beijnen, Jos H ^d,e   Back, David J ^c   Prins, Jan M ^b  

^a Intl Antiviral Ther Eval Center   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d SLOTERVAART HOSPITAL   (Netherlands)

^e UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DEOXYCYTIDINE TRIPHOSPHATE; DEOXYGUANOSINE TRIPHOSPHATE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LIVER ENZYME; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEVIRAPINE; NUCLEOSIDE TRIPHOSPHATE; PHOSPHATE; RITONAVIR;

ADULT; ARTICLE; CELL LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG EFFECT; DRUG HYPERSENSITIVITY; ENZYME BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACOLOGICAL PARAMETERS; PLASMA CLEARANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-RETROVIRAL AGENTS; CYTIDINE TRIPHOSPHATE; DEOXYCYTOSINE NUCLEOTIDES; DEOXYGUANINE NUCLEOTIDES; DRUG INTERACTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MYCOPHENOLIC ACID;

EID: 4744339361     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200443120-00004     Document Type: Article

References (34)

1. van Praag RM, Wit FW, Jurriaans S, et al. Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapy. AIDS 2002; 16 (5): 719-25
2. Weverling GJ, Lange JM, Jurriaans S, et al. Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy. AIDS 1998; 12 (11): F117-22
3. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999; 340 (21): 1605-13
4. Zack JA, Arrigo SJ, Weitsman SR, et al. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 1990; 61 (2): 213-22
5. De Boer RJ, Boucher CA, Perelson AS. Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine. AIDS 1998; 12 (13): 1567-70
6. Lori F, Malykh A, Cara A, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 1994; 266 (5186): 801-5
7. Havlir DV, Gilbert PB, Bennett K, et al. Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression. AIDS 2001; 15 (11): 1379-88
8. Margolis D, Heredia A, Gaywee J, et al. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. J Acquir Immune Defic Syndr 1999; 21 (5): 362-70
9. Chapuis AG, Paolo RG, D'Agostino C, et al. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat Med 2000; 6 (7): 762-8
10. Becker BN. Mycophenolate mofetil. Transplant Proc 1999; 31 (7): 2777-8
11. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47 (2-3): 85-118
12. Allison AC, Eugui EM. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 1993; 136: 5-28
13. Faletto MB, Miller WH, Garvey EP, et al. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob Agents Chemother 1997; 41 (5): 1099-107
14. Stein DS, Moore KH. Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians. Pharmacotherapy 2001; 21 (1): 11-34
15. Hossain MM, Coull JJ, Drusano GL, et al. Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir. Antiviral Res 2002; 55 (1): 41-52
16. Halpern SD, Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. N Engl J Med 2002; 347 (4); 284-7
17. Gummert JF, Barten MJ, Sherwood SW, et al. Pharmacodynamics of immunosuppression by mycophenolic acid: inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics. J Pharmacol Exp Ther 1999; 291 (3): 1100-12
18. Roos MT, Prins M, Koot M, et al. Low T-cell responses to CD3 plus CD28 monoclonal antibodies are predictive of development of AIDS. AIDS 1998; 12 (14): 1745-51
19. Sparidans RW, Hoetelmans RM, Beijnen JH. Liquid chromatographic assay for simultaneous determination of abacavir and mycophenolic acid in human plasma using dual spectrophotometric detection. J Chromatogr B Biomed Sci Appl 2001; 750 (1): 155-61
20. Crommentuyn KM, Rosing H, Nan-Offeringa LG, et al. Rapid quantification of HIV protease inhibitors in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. J Mass Spectrom 2003; 38 (2): 157-66
21. van Heeswijk RP, Hoetelmans RM, Meenhorst PL, et al. Rapid determination of nevirapine in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl 1998; 713(2); 395-9
22. Kewn S, Hoggard PG, Sales SD, et al. Development of enzymatic assays for quantification of intracellular lamivudine and carbovir triphosphate levels in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2002; 46 (1): 135-43
23. Sankatsing SUC, Jurriaans S, van Swieten P, et al. Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naive HIV-1 patients. AIDS. In press
24. Sankatsing SU, Prins JM. Agranulocytosis and fever seven weeks after starting abacavir. AIDS 2001; 15 (18): 2464-5
25. Brunet M, Martorell J, Oppenheimer F, et al. Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetil. Transpl Int 2000; 13 Suppl. 1: S301-5
26. Boehringer Ingelheim Pharmaceuticals. Viramune® (nevirapine): product information. Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals, 1999
27. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998; 34 (6): 429-55
28. Cheeseman SH, Hattox SE, McLaughlin MM, et al. Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. Antimicrob Agents Chemother 1993; 37 (2): 178-82
29. van Gelder T, Klupp J, Barten MJ, et al. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001; 23 (2): 119-28
30. Daluge SM, Good SS, Faletto MB, et al. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob Agents Chemother 1997; 41 (5): 1082-93
31. Margolis DM, Kewn S, Coull JJ, et al. The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA. J Acquir Immune Defic Syndr 2002; 31(1): 45-9
32. Gao WY, Johns DG, Chokekuchai S, et al. Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2′,3′-dideoxynucleoside activities against replication of human immunodeficiency virus. Proc Natl Acad Sci U S A 1995; 92 (18): 8333-7
33. Hoggard PG, Kewn S, Maherbe A, et al. Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea. AIDS 2002; 16 (18): 2439-46
34. Miller WH, Daluge SM, Garvey EP, et al. Phosphorylation of carbovir enantiomers by cellular enzymes determines the stereoselectivity of antiviral activity. J Biol Chem 1992; 267 (29): 21220-4